McMurry-Heath calls for increased transparency on vaccine evaluations

Amid questions of whether FDA has been compromised by political pressure to approve a COVID-19 vaccine ahead of the U.S. presidential election, industry leaders are calling for increased transparency regarding FDA’s vaccine guidelines and pushing back against the politicization of vaccine timelines. 

BIO President and CEO Michelle McMurry-Heath on Friday urged HHS Secretary Alex Azar to publicly release FDA guidance regarding emergency use authorization (EUA) of COVID-19 vaccines to “provide scientists and researchers greater regulatory clarity and strengthen public confidence in any future vaccine that may be authorized or approved.”...